A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
Youdim
Moussa B H
MB
Department of Pharmacology, Technion-Bruce Rappaport Faculty of Medicine, Eve Topf and NPF Neurodegenerative Diseases Centers, Rappaport Family Research Institute, Haifa, Israel. youdim@tx.technion.ac.il
Riederer
Peter F
PF
D000293:Adolescent; D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001479:Basal Ganglia / Q000201:enzymology; D002611:Cheese / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D004298:Dopamine / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007223:Infant; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000502:physiology; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D018377:Neurotransmitter Agents / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology; D012642:Selegiline / Q000494:pharmacology / Q000627:therapeutic use; D014439:Tyramine / Q000009:adverse effects
D000978:Antiparkinson Agents; D008996:Monoamine Oxidase Inhibitors; D009419:Nerve Tissue Proteins; D018377:Neurotransmitter Agents; D012642:Selegiline; D008995:Monoamine Oxidase; D004298:Dopamine; D014439:Tyramine